A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease

Medtronic Spinal and Biologics0 sites134 target enrollmentNovember 1998

ConditionsDegenerative Disc Disease

Overview

Phase: N/A
Intervention: Not specified
Conditions: Degenerative Disc Disease
Sponsor: Medtronic Spinal and Biologics
Enrollment: 134
Primary Endpoint: Overall Success
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study is designed to assess the safety and effectiveness of the rhBMP-2/ACS/LT-CAGE® Device using laparoscopic surgical technique as compared to an historical control group treated with Autogenous Bone/LT-CAGE® Device using an open surgical technique in patients with symptomatic degenerative disc disease.

Registry

clinicaltrials.gov

Start Date

November 1998

End Date

October 2002

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Medtronic Spinal and Biologics

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g.,pain \[leg, back, or symptoms in the sciatic nerve distribution\], function deficit and/or neurological deficit)and radiographic studies ( e.g., CT, MRl, X-Ray, etc.) to include one or more of the following:
•instability( defined as angular motion \> 5° and/or translation \>= 2-4mm, based on Flex/Ext radiographs);
•osteophyte formation;
•decreased disc height;
•thickening of ligamentous tissue;
•disc degeneration or herniation; and/or
•facet joint degeneration.
•Has preoperative Oswestry score \>
•Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.).
•Has single-level symptomatic degenerative involvement from L4 to S

Exclusion Criteria

•Had previous anterior spinal fusion surgical procedure at the involved level.
•Has posterior spinal instrumentation (which will not be removed) stabilizing the involved level or has had a previous posterior lumbar interbody fusion procedure at the involved level.
•Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
•Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
•Has presence of active malignancy.
•Has overt or active bacterial infection, either local or systemic.
•Is grossly obese, i.e., weight \> 40% over ideal for their age and height.
•Has fever ( temperature \> 101° F oral) at the time of surgery.
•Has a documented titanium alloy allergy or intolerance.
•Is mentally incompetent. if questionable, obtain psychiatric consult.

Outcomes

Primary Outcomes

Overall Success

Time Frame: 24 month

A patient will be considered an overall success if all of the following conditions are met: 1. fusion; 2. pain/disability (Oswestry) improvement; 3. maintenance or improvement in neurological status; 4. no serious adverse event classified as implant associated or implant/surgical procedure associated; 5. no additional surgical procedure classified as a "failure."